Thousand Oaks Biologics at CPHI Frankfurt 2025
Thousand Oaks Biologics, a leading Asia-based CRDMO, announced its participation in CPHI Frankfurt 2025, held from October 28-30.
The company will showcase its integrated ADC CRDMO solutions and media innovation for industrialization at Booth 4.1H54 in the Bioproduction Zone.
Thousand Oaks Biologics' service platform is supported by its industrial media supply and driven by AI and innovative drug discovery technologies.
Antibody-drug conjugates (ADCs) are a key driver of China's innovative drug globalization.
Author's summary: Thousand Oaks Biologics showcases ADC solutions at CPHI Frankfurt 2025.